viewOventus Medical Ltd

Oventus Medical will update on new products and increasing revenue at Proactive CEO Sessions

The company’s O2 Vent Optima device was launched in both Australia and Canada during the March quarter.

O2 Vent Optima device
US launch expected in mid-CY2019

Oventus Medical Ltd’s (ASX:OVN) cash receipts increased to $100,000 for the quarter ended March 31 2019, up from $47,000 in the prior quarter.

The improved revenue result was driven primarily by sales increasing in Australia, due to the launch of Oventus’ new lightweight nylon O2 Vent Optima devices for the treatment of OSA (obstructive sleep apnoea) and snoring.

Oventus managing director Dr Chris Hart will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.

Dr Chris Hart

New product to improve airflow and airway stability

O2 Vent Optima is the first of two new products coming to market in 2019.

The second product is a valve that integrates with select O2 Vent devices to naturally improve airflow and airway stability.

The valve is called the ExVent and in combination with Oventus’ Airway Technology, has been clinically proven to dramatically increase the success rates over traditional mouthguard devices for sleep apnoea sufferers.

Highly anticipated product

Following the Australian release of ExVent, the product will be launched in North America and Europe, subject to regulatory approval.

This new treatment modality is highly anticipated by the sleep community and, along with O2 Vent Optima is potentially transformational for the company.

Register for the CEO Sessions today

Sydney details, Monday, May 13, 2019

Melbourne details, Tuesday, May 14, 2019

Also featuring at both sessions will be Xanadu Mines Ltd (ASX:XAM), Infinity Lithium Ltd (ASX:INF), Zelda Therapeutics Ltd (ASX:ZLD) and Invitrocue Ltd (ASX:IVQ).

Quick facts: Oventus Medical Ltd

Price: 0.235 AUD

Market: ASX
Market Cap: $37.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oventus Medical Ltd named herein, including the promotion by the Company of Oventus Medical Ltd in any Content on the Site, the Company...


Oventus Medical targeting massive growth in North America with Sleep Apnea...

Oventus Medical (ASX: OVN) Managing Director Dr Chris Hart joined Steve Darling from Proactive to discuss the medical device company that has a unique treatment platform for sleep apnea and snoring. Hart telling Proactive about their growth strategy and also about two deals they recently signed...

on 06/08/2020

2 min read